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Schizophrenia is a severe brain disorder that is associated with neurodevelopmental
insults, such as prenatal inflammation, that introduce redox-immune-inflammatory
alterations and risk for psychotic symptoms later in life. Nutraceuticals may offer useful
adjunctive benefits. The aim of this study was to examine the therapeutic effects of
Garcinia mangostana Linn (GML) and one of its active constituents, α-mangostin (AM),
alone and as adjunctive treatment with haloperidol (HAL) on schizophrenia related
bio-behavioral alterations in a maternal immune-activation (MIA) model. Sprague–Dawley
dams were exposed to lipopolysaccharide (LPS) (n= 18) or vehicle (n= 3) on gestational
days 15 and 16. Male offspring (n = 72) were treated from PND 52–66 with either
vehicle, HAL (2 mg/kg), GML (50 mg/kg), HAL + GML, AM (20 mg/kg), or HAL +
AM. Control dams and control offspring were treated with vehicle. In order to cover
the mood–psychosis continuum, prepulse inhibition (PPI) of startle, open field test
(locomotor activity), and the forced swim test (depressive-like behavior) were assessed
on PND’s 64–65, followed by assay of frontal–cortical lipid peroxidation and plasma
pro-inflammatory cytokines, viz. interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α).
MIA-induced deficits in sensorimotor gating were reversed by HAL and HAL + GML, but
not GML and AM alone. MIA-induced depressive-like behavior was reversed by AM and
GML alone and both in combination with HAL, with the combinations more effective than
HAL. MIA-induced cortical lipid peroxidation was reversed by HAL and AM, with elevated
IL-6 levels restored by GML, AM, HAL, and HAL + GML. Elevated TNF-α was only
reversed by GML and HAL + GML. Concluding, prenatal LPS-induced psychotic- and
depressive-like bio-behavioral alterations in offspring are variably responsive to HAL,
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GML, and AM, with depressive (but not psychosis-like) manifestations responding
to GML, AM, and combinations with HAL. AM may be a more effective antioxidant than
GML in vivo, although this does not imply an improved therapeutic response, for which
trials are required.
Keywords: antidepressant, oxidative stress, immunity, antipsychotic, complimentary medicine, maternal
inflammation, mangosteen, adjunctive treatment
INTRODUCTION
Schizophrenia is a severe psychiatric disorder with a chronic
course, affecting ∼1% of the global population (1). This
debilitating disease manifests in early adulthood (2), presenting
with positive (hallucinations and delusions), negative (social
withdrawal, apathy, and anhedonia), and cognitive symptoms
(working memory deficits, attention disorders, and altered
information processing) (3). However, the underlying etiological
mechanisms remain elusive (4). Similarly, the treatment outcome
for schizophrenia remains suboptimal (5), especially with regard
to negative and cognitive symptoms (6, 7).
The neurodevelopmental hypothesis has provided a valuable
framework for establishing the relationship between pathologic
processes during early brain development and the development
of schizophrenia later in life (8, 9). This hypothesis suggests
an interaction between genetic predisposition and early life
environmental vulnerability factors such as malnutrition,
substance abuse, obstetric complications, season of birth and
infection, and exacerbation by later stresses such as substance
abuse, social defeat, and trauma (10–13).
Viral or bacterial maternal infection during pregnancy has
been linked to increased risk for developing schizophrenia in
the offspring (14, 15), with immune activation rather than the
infectious agent, itself, being deemed causal (16, 17). Indeed,
trauma is associated with immune activation and increased risk
of psychosis (18). Immune adjuvants such as lipopolysaccharide
(LPS) (19–21), polyinosinic:polycytidylic acid (poly I:C) (22–24),
human influenza virus (25), and cytokines (26, 27) induce diverse
biological and behavioral abnormalities in rodents following
prenatal maternal exposure. LPS, an endotoxin derived from
the cell wall of Gram-negative bacteria, mimics an infection
by activating the synthesis and release of pro-inflammatory
cytokines, including interleukin-1β (IL-1b), IL-6, and tumor
necrosis factor-α (TNF-α) (28–30) and engenders various
schizophrenia-like behavioral, neurochemical, and inflammatory
changes (31–33).
Abbreviations: AM, α-mangostin; ANOVA, analysis of variance; ARRIVE,
Animal Research: Reporting in vivo Experiments; cAMP, cyclic adenosine
monophosphate; DAD, diode-array detection; FST, forced swim test;
GML, Garcinia mangostana Linn; HAL, haloperidol; HPLC, high-pressure
liquids chromatography; IL, interleukin; LPS, lipopolysaccharide; MDA,
malondialdehyde; MIA, maternal immune activation; NAC, N-acetyl cysteine;
NWU, North-West University; OFT, open field test; PBS, phosphate-buffered
saline; PDE, phosphodiesterase; PEG, polyethylene glycol; PND, post-natal day;
Po, per os; Poly I:C, polyinosinic,polycytidylic acid; PPI, prepulse inhibition; SD,
Sprague–Dawley; TBARS, thiobarbituric acid reactive substance; TNF, tumor
necrosis factor.
Oxidative stress underscores various psychiatric conditions
(34, 35), in particular, schizophrenia (36). Increased reactive
oxygen species (ROS) and reduced antioxidants observed in
schizophrenia may contribute to the neuroprogression of the
disorder (37) and to the development of cognitive dysfunction
(38, 39). Indeed, the antioxidant, N-acetyl cysteine (NAC), has
therapeutic benefits in various clinical domains of schizophrenia,
but especially negative symptoms (40, 41) and cognition (42),
while having also demonstrated efficacy in preclinical animal
models (43–45).
There is an increased drive to integrate nutraceuticals
and psychotropic herbal medicines into conventional medical
practice (46). Co-prescription of certain herbal medicines
with traditional pharmaceuticals may display complementary
pharmacodynamic actions and so provide a beneficial synergistic
effect (46, 47). However, little study has occurred that has directly
explored such augmentation effects (46).With raw herbal extracts
containing a vast array of potentially bioactive ingredients, the
question remains whether the observed pharmacological effect is
ingredient specific or a sum effect of the total extract.
The anti-inflammatory and antioxidant activities of herbal
bioactive compounds have been widely observed, particularly in
a group of polyphenols referred to as xanthones (48). Garcinia
mangostana Linn (GML) is a fruit native to Southeast Asia
known to contain constituents including xanthones, flavonoids,
triterpenoids, and benzophenones (49). Extracts of the fruit
have exhibited antioxidant (50, 51), anti-inflammatory (52, 53),
antibacterial (54), and antidepressant effects (55). In particular,
α-mangostin (AM), a primary component of GML, presents
with substantial pharmacological properties (56, 57), including
antioxidant activity (58), as well as having moderate inhibitory
effects on 5HT2A receptors and cyclic adenosine monophosphate
(cAMP) phosphodiesterase (PDE) (49), actions that hint at
possible clinical utility as a pharmacological intervention in
psychiatric disorders.
The aim of this study was to establish whether maternal
immune activation (MIA) induced schizophrenia-like behavior
and redox-inflammatory alterations in offspring can be reversed
with the typical antipsychotic, haloperidol (HAL), GML, and AM
separately. Second, since themost common use for nutraceuticals
in clinical psychiatry is as an adjunctive treatment (46), we
investigated whether adjunctive treatment with GML or AM is
able to augment the response to HAL. The inclusion of AM
is 2-fold; to investigate whether any observed pharmacological
effects of GML may be specific for one of the known bio-active
constituents of the extract, i.e., AM, or whether these actions
underscore a sum effect of the total extract and, second, to link
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any effects to a known psychotropic property of AM and/or GML.
In order to cover the mood-psychosis continuum, behavioral
analyses focused on positive (sensorimotor gating; locomotor
hyperactivity) and negative (depression) related symptoms.
Moreover, by measuring associated changes in plasma and brain
redox-inflammatory markers, it explores possible activity within
a key neuropathological feature of the illness, viz. immune-
inflammatory dysfunction (35). This study has importance to
the field in that a plant extract and one of its known bioactive
constituents are compared to a reference control pharmaceutical
agent across a range of behavioral and biological parameters of
relevance to schizophrenia.
METHODS AND MATERIALS
Chromatographic Fingerprinting of Raw
GML
In order to determine the authenticity and constituents of
GML, separation of prenylated xanthones found in GML
was achieved utilizing reversed-phase high-performance liquid
chromatography (HPLC) with diode-array detection (DAD) [see
Oberholzer et al., (55)].
Animals
Pregnant female Sprague–Dawley (SD) dams were used during
the prenatal phase of the study.Male pups were weaned (PND 21)
and used for the remainder of the study. Since this and our earlier
paper (55) represent the first bio-behavioral studies evaluating
the possible psychotropic benefits of GML in translational rodent
models of neuropsychiatric illness, and that the hormone cycle of
female rats is well known to influence the outcome of behavioral
and pharmacological studies, e.g., Regenass et al. (59) and Harvey
et al., (60), only male rats were used in the study.
In order to remove experimental bias, animals were randomly
allocated by an experienced animal technologist blind to the
study (61) to 12 rats per group (62). The number of rats per
group was as directed by a statistical power analysis. Animals
were bred, supplied, and housed at the Vivarium (South African
Veterinary Council reg. no. FR15/13458; South African National
Accreditation System good laboratory practice compliance no.
G0019) of the Pre-Clinical Drug Development Platform of the
North-West University (NWU) in identical cages containing
corncob, under conditions of constant temperature (22 ± 1◦C)
and humidity (50 ± 10%) with a 12:12-h light/dark cycle
(lights on 06:00 to 18:00). Food and water were provided ad
libitum in the home cage, with corncob changed at least once a
week. All experiments were approved by the AnimCare animal
research ethics committee (National Health Research Ethics
Council reg. no. AREC-130913-015) of the NWU. Animals were
maintained, and all procedures performed in accordance with
the code of ethics in research, training, and testing of drugs
in South Africa and complied with national legislation (Ethical
approval numbers: NWU-00376-16-A5 and NWU-00147-14-
A5). The study design and procedures were according to the
Animal Research: Reporting in vivo Experiments (ARRIVE)
Guidelines (61).
Study Design
The exposure and treatment layout of the MIA model is
presented in Figure 1. Treated dams (n = 18) received LPS from
gestational days 15–16 with control dams (n= 3) receiving saline
from gestational days 15–16. These GDs were chosen on the
grounds of a previous study showing decreased fetal demise at
this stage, as well as the correlation of this period with second
trimester human pregnancy, suspected to be a critical period
for the development of schizophrenia (63). Male offspring (±4
per dam) was used in the remainder of the study. A previous
study did not demonstrate protective effects of cross-fostering in
a MIA model (64). Off-spring was therefore not cross-fostered
with healthy dams.
A total number of 72 male offspring from LPS-exposed dams
(n = 72) were randomly divided into six treatment groups, each
comprising 12 rats/group (65). These groups received oral dosing
of the following: vehicle (saline, 1 ml/kg), HAL (2 mg/kg po)
(66–69); GML (50 mg/kg po) (55), HAL + GML (HAL + GML)
(at the previously mentioned doses), AM (20 mg/kg po) (70)
and haloperidol + α-mangostin (HAL + AM) (at the previously
mentioned doses) (Figure 1). Male offspring from the control
dams (n= 8) received oral dosing of vehicle. The respective drug
treatments continued for 16 days from PND 51–66 (55). During
the last 2 days of treatment, all groups were subject to behavioral
testing as follows: (1) prepulse inhibition (PPI) of startle on day
13 of treatment (PND 63), (2) the open field test (OFT) on day 14
of treatment (PND 64), and the forced swim test (FST) on day 14
of treatment (PND 64). The animals were euthanized 36 h later
by decapitation with trunk blood and brain tissue collected and
stored at−80◦C for later neurochemical analysis.
Drugs and Treatment
LPS (100 µg/kg) from Escherichia coli (E. coli) (Sigma-Aldrich,
Johannesburg, South Africa) was dissolved in saline and
administered subcutaneously (SC) to pregnant dams on GD 15–
16 (30, 63). HAL (2 mg/kg/day; Sigma-Aldrich, Johannesburg,
South Africa) was dissolved in a minimum volume of glacial
acetic acid, then further diluted with distilled water and the
pH adjusted using 10N NaOH to 6–6.25 and administered by
oral gavage (66). The dose of HAL was selected for oral dosing
specifically and in line with an earlier study (71). The ground
dried pericarp of GML fruit (Industrial Analytical, Kyalami,
South Africa) was mixed in a 0.1% xanthan gum solution to
aid suspension and administered by oral gavage, at a dose of
50 mg/kg/day (55). AM (Sigma-Aldrich, Castle Hill, Australia)
was dissolved in polyethylene glycol (PEG) 400 vehicle (PEG
400:water ratio = 6:4, v/v) (72) and administered orally (20
mg/kg/day) (70).
Behavioral Analyses
In order to assess whether the applied drug treatments are
equally effective with respect to mood vs. psychosis-related
manifestations of schizophrenia, PPI of startle (psychosis
like), locomotor activity, and despair in the FST (depressive
like) behaviors were assessed on PND’s 64–65. Indeed, an
earlier study found GML to be an effective antidepressant
vs. imipramine using a genetic rodent model of depression
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FIGURE 1 | Schematic diagram of the study layout.
(55). The current study design would not only re-affirm the
earlier noted observation but do so in another translational
model, while it would also possibly extend GML’s scope of
application to psychotic disorders like schizophrenia. This
approach has validity since MIA not only evokes psychosis-
like behavior in rat offspring (31–33) but also depressive-
like manifestations (21), thereby presenting its suitability
for studying broad pharmacological responses of relevance
to schizophrenia.
Prepulse Inhibition (PPI)
PPI is used to determine deficits in sensorimotor gating,
well described in schizophrenia (73) and representative of
cognitive fragmentation (74). PPI was assessed in illuminated
and ventilated sound-attenuated startle chambers (SR-LAB, San
Diego Instruments, San Diego, USA), as described previously
(75). Startle amplitudes were defined as the average of 100× 1-ms
stabilimeter readings collected at stimulus onset. The stabilimeter
was calibrated before each session.
Briefly, the startle session began with a 5-min acclimatization
period, during which a 68-dB background noise level was
maintained throughout the session; the basal startle response was
thenmeasured with 10 trials of a single 40-ms 120-dB white noise
as a startle stimulus; after this, 80 trials of randomly delivered
pulses, including 20 trials of 120 dB PULSE-ALONE trials, 50
PREPULSE trials (with intensities of 72, 76, 80, or 84 dB) and
10 trials with no pulse was delivered. A final 10 trials of single
40-ms 120-dB PULSE-ALONE startle stimuli was then supplied.
After the testing session, the percentage PPI (%PPI) for the
four pre-pulse intensities was calculated as %PPI = [100–(startle
response for PREPULSE + PULSE trial)/(startle response for
PULSE ALONE trial)× 100].
Open Field Test (OFT)
The OFT was used to exclude any confounding locomotor
effects of treatment in the FST (76). Moreover, motor activity
in the OFT may be indicative of underlying neurotransmitter
alterations, especially subcortical dopaminergic hyperactivity
that has relevance to schizophrenia (77). Rats were tested
individually in an open field arena (1 × 1m), with total distance
moved (cm) scored for 5min using EthoVision XT R© software
(Noldus Information Technology, Wageningen, Netherlands).
Forced Swim Test (FST)
The FST was used to screen for antidepressant-like properties
following prenatal LPS exposure and drug treatment (78, 79).
Negative symptoms of schizophrenia are closely related to
depressive behavior (80), while schizophrenia is often co-
morbid with major depression (81). The FST was performed
as described previously (82), except the final swim was over a
period of 7min with the first and last minute discarded during
analysis (55). Immobility time was scored as floating behavior
with the rat maintaining only the necessary movements to
keep its head above the water vs. escape-directed swimming
(horizontal movements throughout the cylinder) and struggling
or climbing (upward-directed movements in cylinder) behavior
(76). The latter are noted for representing serotonergic and
noradrenergic-mediated escape-directed behaviors, respectively
(82). These behavioral components were recorded and scored
on video by investigators blind to treatment, expressed in units
of time (s). Behavior was scored using manual continuous
timer software (FST Scoreboard 2.0 software; Academic Support
Services: Information Technology in Education, NWU),
previously validated against the traditional 5-s time-sampling
technique (83).
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Brain Tissue and Plasma Preparation
Thirty-six hours after the final behavioral analysis, rats were
euthanized by decapitation, after which trunk blood was collected
into pre-chilled, 4-ml vacutainer tubes (SGVac) containing
dipotassium ethylenediaminetetraacetic acid (K2EDTA) solution
as anticoagulant. Frontal cortex and striatum were dissected out
on an ice-cooled glass slab as described previously (62, 84). Liquid
nitrogen was used to fix the above brain regions and stored at
−80◦C until the day of analysis. The tissue was pre-split into
aliquots for use in the different assays to avoid freeze–thaw–
freeze changes and possible deactivation of components. On the
day of assay, the tissue was weighed and allowed to thaw on ice.
A 10% tissue homogenate was then prepared in a phosphate-
buffered saline (PBS) using a Teflon homogenizer (84).
Lipid Peroxidation Analysis
Thiobarbituric acid reactive substance (TBARS) is a by-product
of lipid peroxidation. The ParameterTM TBARS assay from R&D
Systems (Minneapolis, USA; catalog number KGE013) was used
to analyze lipid peroxidation in brain tissue (45), according to
the manufacturer’s instructions. Absorbance was read at 532 nm
using a Bio-Tek FL600Microplate Fluorescence Reader (Bio-Tek,
Instruments, Inc., 381 Highland Park, Winooski, VT, USA).
Pro-inflammatory Cytokine Measurement
Plasma TNF-α was measured using the Rat TNF-α ELISA
MAXTM Deluxe Set (catalog number 438204) from Bio Legend
(San Diego, USA). IL-6 was measured using the Rat IL-6
ELISA Kit (catalog number E-EL-R0015) from Elabscience R©
(Wuhan, China). Both were performed in accordance with the
manufacturer’s instructions. Absorbance was read at 450 nm
using the above noted instrument.
Statistical Analyses
One-way factorial analysis of variance (ANOVA) and Bonferroni
post hoc tests were used for the statistical analyses of FST
scores, brain lipid peroxidation levels, and plasma cytokine
analyses. For analysis of %PPI data, two-way ANOVA with
repeated measures was used with Bonferroni post hoc tests.
However, in order to compare the MIA model with the control
group, an unpaired Student’s t-test was used to analyze each
parameter. To ensure there is complete equality of the variances
of the differences between all variations of related groups,
assumption of sphericity was conducted with Mauchly’s test.
If the assumption of sphericity was not met, the Greenhouse–
Geisser correction was used. Normal distribution of the variables
was assessed with a Q–Q plot and histogram for all variables in
each treatment group. All data were normally distributed and
expressed as the mean± standard error of the mean (SEM), with
a value of p < 0.05 considered statistically significant. Where
additional detail was deemed useful, for example, when statistical
significance was narrowly missed, a Cohen’s d calculation was
performed to establish effect size and practical significance:
medium effect (0.5 ≥ d < 0.8), large effect (0.8 ≥ d < 1.3),
and very large effect (d ≥ 1.3) sizes. Only large-to-very large
effect sizes are presented in the figures and text. All data were
analyzed and graphics prepared using GraphPad Prism 7, San
Diego California, USA.
RESULTS
MIA model validation, i.e., LPS vs. saline control, was analyzed
separately using T-tests and presented in Figures 2–6. Thereafter,
untreated LPS (MIA model) were compared to LPS plus the
various drug treatments and analyzed separately using the
appropriate ANOVA followed by post hoc Bonferroni analysis.
The latter are also presented in Figures 2–6.
GML Fingerprinting
A chromatogram of GML used in this study, and analyzed
using reversed-phase HPLC with DAD, was found to
contain predominantly α-mangostin (11.7%) and γ-mangostin
(1.1%) (55).
TREATMENT-NAIVE LPS- VS.
SALINE-EXPOSED ANIMALS (MIA MODEL
VALIDATION) (FIGURES 2–6)
Prepulse Inhibition of Acoustic Startle
When considering the LPS model alone compared to the vehicle
control group, unpaired Student’s t-tests revealed no significant
differences between the groups at the respective startle blocks
(data not shown).
Regarding %PPI and comparing the LPS-exposed group to the
vehicle group using unpaired Student’s t-tests, the LPS-exposed
control group (LPS + vehicle) presented with significant deficits
in %PPI at 72 dB (p = 0.0248), 76 dB (p = 0.003), 80 dB (p =
0.007), and 84 dB (p = 0.007) when compared to the control
group (saline+ vehicle) (Figures 2A–D).
Open Field Test
Unpaired Student’s t-test revealed a significant increase in
locomotor activity in the LPS exposed group (LPS + vehicle)
compared to the saline control group (saline + vehicle) (p =
0.039) (Figure 3).
Forced Swim Test
Unpaired Student’s t-test revealed a significant increase in
immobility in the LPS-exposed rats (LPS + vehicle) when
compared to the control group (saline + vehicle) (p < 0.0001)
(Figure 4A). A significant decrease in both swimming (p =
0.0002) (Figure 4C) and struggling (p < 0.0001) (Figure 4B)
behaviors was also observed in the LPS-exposed group (LPS +
vehicle) compared to the control group (saline+ vehicle).
Regional Brain Lipid Peroxidation
Using unpaired Student’s t-tests, frontal cortical malondialdehyde
(MDA) levels were significantly increased in the LPS-exposed rats
(LPS+ vehicle) (p= 0.030), compared to the saline control group
(saline + vehicle) (Figure 5A). In the striatum, significantly
Frontiers in Psychiatry | www.frontiersin.org 5 March 2020 | Volume 11 | Article 121
Lotter et al. Antidepressant and Antipsychotic Actions of Mangosteen
FIGURE 2 | Sensorimotor gating with regard to percent prepulse inhibition (%PPI) of startle at (A) 72 dB, (B) 76 dB, (C) 80 dB, and (D) 84 dB in rats exposed to
saline and treated with vehicle (Control) as well as rats exposed to LPS receiving vehicle and the various drug treatments as indicated [unpaired Student’s t-test for
Control vs. LPS + vehicle; ∧p < 0.05, ∧∧p < 0.01; two-way ANOVA with repeated measures for the different dB intensities, Bonferroni post hoc test; *p < 0.05, **p <
0.01 vs. LPS + Vehicle. $d ≥ 1.3 vs. LPS + Vehicle (Cohen’s d value)].
elevated levels of MDA were also observed in the LPS-exposed
rats (LPS + vehicle) (p < 0.0001) in comparison with the saline
control group (saline+ vehicle) (Figure 5B).
Cytokines
IL-6
Unpaired Student’s t-test revealed that plasma IL-6 levels were
significantly elevated in the LPS-exposed group (LPS + vehicle)
when compared to the saline control group (saline + vehicle) (p
= 0.0005) (Figure 6A).
TNF-α
Unpaired Student’s t-test displayed significantly elevated plasma
TNF-α levels in the LPS-exposed group (LPS + vehicle) when
compared to their saline control group (saline + vehicle) (p =
0.041) (Figure 6B).
LPS MODEL PLUS VARIOUS DRUG
TREATMENTS (FIGURES 2–6)
Prepulse Inhibition of Acoustic Startle
Two-way ANOVA with repeated measures for each startle block
in all the groups receiving the respective treatment or vehicle
indicated a significant treatment × startle block interaction
[F(3,73) = 67.69, p < 0.0001] but no significant main effect of
startle block [F(3, 73) = 1.62, p = 0.128] or treatment [F(3, 73)
= 1.023, p = 0.417] on startle amplitude (data not shown).
Bonferroni post hoc testing on the startle amplitude in all
the LPS-exposed groups receiving the respective treatments or
vehicle indicated that all the groups had a significant decrease
(p < 0.05) in startle amplitude from blocks 1 to 4 (data not
shown). Bonferroni post hoc testing also revealed no significant
differences between any of the exposed and treatment groups at
the respective startle blocks.
When considering drug treatment in the LPS model
(Figure 2), two-way ANOVA revealed a significant interaction
between treatment and PPI intensity [F(6, 77) = 295.66, p <
0.0001] as well as a significant main effect of treatment [F(6, 77)
= 5.63, p < 0.0001] and PPI intensity [F(6, 77) = 1.83, p = 0.04]
on %PPI in all the groups receiving the respective treatments
or vehicle. Bonferroni post hoc testing demonstrated that HAL
significantly reversed %PPI deficits in the LPS-exposed rats
at 72 dB (p = 0.009) (Figure 2A) and 76 dB (p = 0.032)
(Figure 2B). However, a very large effect size was observed
in the LPS-exposed HAL-treated rats compared to their LPS
vehicle-treated controls at 80 dB (d = 1.7) and 84 dB (d =
1.6) (Figures 2C,D, respectively). The combination treatment
of GML + HAL successfully reversed %PPI deficits at all four
of the prepulse intensities: 72 dB (p = 0.017), 76 dB (p =
0.002), 80 dB (p = 0.003), and 84 dB (p = 0.014) vs. the LPS-
exposed control group (Figures 2A–D, respectively). However,
no significant differences were observed in the LPS-exposed rats
treated with GML alone, AM alone, or the combination of HAL
+ AM vs. the LPS+ vehicle-exposed group (Figures 2A–D).
Open Field Test
A one-way ANOVA of the OFT data in all the groups receiving
the respective treatments or vehicle revealed a significant main
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FIGURE 3 | Locomotor activity (total distance moved in cm), analyzed in the
OFT in rats exposed to saline and treated with vehicle (Control) as well as rats
exposed to LPS receiving vehicle and the various drug treatments as indicated
(unpaired Student’s t-test for Control vs. LPS + vehicle; ∧p < 0.05; one-way
ANOVA, Bonferroni post hoc test; **p < 0.01 vs. LPS + Vehicle).
effect of treatment on total distance moved [F(6, 75) = 14.43, p
< 0.0001]. When considering drug treatment in the LPS model,
Bonferroni post hoc tests revealed no significant differences in
the total distance moved in the LPS-exposed treatment groups
receiving HAL, GML, HAL + GML, and HAL + AM when
compared to the LPS-exposed control group (LPS + vehicle)
(Figure 3). However, a significant decrease in locomotor activity
was observed in the LPS-exposed group treated with AM (p =
0.006) compared to the control group (LPS+ vehicle) (Figure 3).
Forced Swim Test
A one-way ANOVA of all the groups revealed a significant main
effect of treatment on immobility [F(6, 77) = 16.02, p < 0.0001],
struggling [F(6, 77) = 15.44, p < 0.0001], and swimming [F(6, 77)
= 12.85, p < 0.0001]. When considering drug treatment in
the LPS model (Figure 4), Bonferroni post hoc testing indicated
a significant decrease in immobility in all the LPS-exposed
treatment groups receiving GML (p < 0.0001), AM (p = 0.004),
HAL + GML (p < 0.0001), and HAL + AM (p < 0.0001)
compared to the LPS-exposed control group (LPS + vehicle)
(Figure 4A). The effect of HAL alone did not reach significance
(Figure 4A). However, treatment with GML alone (p = 0.034),
HAL + GML (p < 0.0001), and HAL + AM (p = 0.03) showed
a significantly greater decrease in immobility when compared to
the HAL-treated LPS-exposed group (Figure 4A).
With regard to struggling behavior in the LPS-exposed rats,
HAL (p= 0.005), HAL+ GML (p < 0.0001), and HAL+ AM (p
< 0.0001) displayed a significant increase in struggling compared
to the LPS-exposed control group (LPS + vehicle) (Figure 4B).
The combination treatment of HAL + GML in the LPS rats
displayed a significantly greater increase in struggling behavior
(p = 0.049) when compared to HAL treatment alone in the LPS
rats (Figure 4B).
Swimming behavior was significantly increased in the
LPS groups receiving GML (p < 0.0001) and AM (p <
0.0001) treatment compared to the LPS-exposed control group
(Figure 4C). A significant increase in swimming behavior was
observed between the LPS-exposed group receiving HAL alone
FIGURE 4 | The forced swim test (FST) with regard to (A) immobility, (B)
struggling, and (C) swimming behavior in rats exposed to saline and treated
with vehicle (Control) as well as rats exposed to LPS receiving vehicle and the
various drug treatments as indicated (unpaired Student’s t-test for Control vs.
LPS + vehicle; ∧∧p < 0.01, ∧∧∧p < 0.001; one-way ANOVA, Bonferroni post
hoc test; **p < 0.01, ****p < 0.0001 vs. LPS + Vehicle; #p < 0.05 vs. LPS +
HAL).
vs. both the LPS-exposed groups receiving GML (p = 0.005) or
AM (p= 0.004), respectively (Figure 4C).
Regional Brain Lipid Peroxidation
One-way ANOVA showed a significant main effect of treatment
on lipid peroxidation in the frontal cortex [F(6, 78) = 5.234,
p < 0.0001] and the striatum [F(6, 77) = 3.956, p = 0.002].
When considering drug treatment in the LPS model (Figure 5),
Bonferroni post hoc analysis revealed that treatment with HAL
(p = 0.001) and AM (p = 0.02) significantly reduced frontal
cortical MDA levels in LPS-exposed rats, compared to the LPS-
exposed control group (LPS + vehicle), but was unaffected by
any of the other LPS-exposed treatment groups (LPS + GML,
LPS + HAL + GML, and LPS + HAL + AM) vs. the LPS-
exposed control group (Figure 5A). GML and GML + HAL
showed a trend toward reducing MDA levels, with a large (d
= 1.0) and medium (d = 0.7) effect size observed in the LPS-
exposed rats treated with GML and GML + HAL, respectively,
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FIGURE 5 | Lipid peroxidation as quantified by malondialdehyde (MDA)
accumulation in (A) frontal cortex and (B) striatum in rats exposed to saline
and treated with vehicle (Control) as well as rats exposed to LPS receiving
vehicle and the various drug treatments as indicated [unpaired Student’s t-test
for Control vs. LPS + vehicle; ∧p < 0.05, ∧∧∧p < 0.0001; one-way ANOVA,
Bonferroni post hoc test; *p < 0.05, ***p < 0.001 vs. LPS + Vehicle. $d = 0.5
≥ d < 0.8, $$d = 0.8 ≥ d < 1.3 vs. LPS + Vehicle (Cohen’s d value)].
FIGURE 6 | Plasma cytokine levels of (A) IL-6 and (B) TNF-α in rats exposed
to saline and treated with vehicle (Control) as well as rats exposed to LPS
receiving vehicle and the various drug treatments as indicated (unpaired
Student’s t-test for Control vs. LPS + vehicle; ∧p < 0.05, ∧∧p < 0.001;
one-way ANOVA, Bonferroni post hoc test; **p < 0.01, ***p < 0.001, ****p <
0.0001 vs. LPS + Vehicle; #p < 0.05 vs. LPS + HAL).
compared to their vehicle-treated controls (Figure 5A). Finally,
none of the respective treatments showed a significant reduction
in striatal MDA levels in the LPS-exposed rats compared to the
LPS-exposed control group (Figure 5B).
Cytokines
IL-6
One-way ANOVA revealed a significant main effect of treatment
on IL-6 [F(6, 76) = 5.93, p < 0.0001] in the LPS and vehicle-
exposed and treated groups.When considering drug treatment in
the LPS model (Figure 6A), Bonferroni post hoc analyses showed
that treatment with HAL (p = 0.021), GML (p = 0.002), AM (p
< 0.0001), and HAL + GML (p = 0.01) significantly reversed
elevated levels of IL-6 in the LPS-exposed groups. However, HAL
+ AM had no significant effect on IL-6 plasma levels in the LPS-
exposed animals compared to the vehicle control (Figure 6A).
TNF-α
One-way ANOVA revealed a significant main effect of treatment
on TNF-α levels [F(6,77) = 5.96, p < 0.0001] in the LPS
and vehicle-exposed groups receiving the respective treatments
(Figure 6B). When considering drug treatment in the LPS model
(Figure 6B), Bonferroni post hoc testing displayed that GML
treatment successfully reversed elevated TNF-α levels in the LPS-
exposed rats when compared to the LPS-exposed control group
(LPS + vehicle) (p < 0.0001) (Figure 6B). In addition, GML
was significantly more effective in decreasing plasma TNF-α
levels in LPS-exposed animals than theHAL-treated LPS-exposed
group (LPS + HAL) (p = 0.0081) (Figure 6B). Treatment with
HAL + GML also significantly reduced TNF-α plasma levels in
LPS-exposed animals in comparison to the LPS-exposed control
group (p = 0.004) (Figure 6B). The remaining three treatment
groups viz. HAL, AM, and HAL + AM showed no significant
reduction in plasma levels of TNF-α when compared to the
LPS-exposed control group (LPS+ vehicle) (Figure 6B).
DISCUSSION
MIA induced sensorimotor gating deficits and depressive-
like behavior concurrent with elevated cortico-striatal lipid
peroxidation and elevated plasma pro-inflammatory cytokines in
offspring. HAL reversed the changes in PPI, cortical (not striatal)
lipid peroxidation, and elevated plasma IL-6, but failed to reverse
depressive manifestations. GML + HAL effectively reversed PPI,
while GML, AM, and HAL+ AM did not. Conversely, GML and
AM alone reversed depressive-like behaviors, more so than HAL,
while the GML + HAL combination also reversed depressive-
like symptoms. AM reversed both cortical (not striatal) lipid
peroxidation and elevated plasma IL-6. GML and HAL + GML
reversed elevations in IL-6 and TNF-α. These data present
evidence for GML and its active constituent, AM, as being
effective as adjunctive treatments but differently active with
respect to psychotic and mood-related behaviors.
In line with previous findings (22, 31, 45, 63, 85), prenatal
LPS exposure significantly compromised PPI in late adolescent
offspring (Figure 2). HAL significantly reversed PPI deficits at
72 and 76 dB, with a similar trend and very large effect sizes
at 80 and 84 dB (Figure 2), consistent with data from previous
chronic (86) and acute (87–89) treatment studies in animals.
Overactive dopaminergic processes are suggested to underlie the
reduction in PPI (90), which explains the ability of HAL (D2
antagonist) to reverse said deficits (91). Although GML + HAL
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was effective in reversingMIA-induced PPI deficits across all four
startle responses, this was not the case for GML or AM separately
or for AM + HAL (Figure 2). The latter suggests that AM may
abrogate the antipsychotic-like response to HAL, a particular
interesting finding. In fact, AM presents with known antioxidant
(58), 5HT2A, and a cAMP-PDE inhibitory (49) activity that to
varying degrees may underlie these effects. Certainly, 5HT2A
receptors play a prominent role in psychotic-like behavior (35) as
well as in atypical antipsychotic drug design (35), and hence may
play a role in the results described here. On the other hand, HAL
is a potent pro-oxidant (92) and pro-inflammatory agent (93).
Depending on the stage of disease progression, these actions,
together with potent D2 inhibition, may mediate HAL’s useful
antipsychotic effects. However, these same pro-oxidative actions
are purported to cause striatal toxicity and to cause late-onset
treatment-related complications (92, 93). Although speculative,
could these actions of HAL be countered by the antioxidant
and cAMP-PDE inhibitory actions of AM, and possibly even
reverse its antipsychotic effects? This opens up new ideas on how
antipsychotics work and warrants further study.
Locomotor hyperactivity represents positive symptom
schizophrenia, especially psychotic agitation (94). Prenatal LPS-
exposed offspring demonstrated increased locomotor activity
in the OFT (Figure 3), a behavioral response that has been
ascribed to hyperdopaminergia (95). HAL lowered LPS-induced
locomotor hyperactivity, albeit not significantly, in line with its
antidopaminergic/antipsychotic actions. Only AM effectively
reduced hyperlocomotion (Figure 3), yet it failed to alter PPI
deficits (noted above). AM is a selective, competitive histamine
antagonist (96) with sedative properties (97) that may adversely
affect startle response in the PPI test. That said, the study design
did not allow us to assess the effects of drug treatments on startle
response in healthy controls, although rats exposed to LPS +
AM did not differ significantly to rats exposed to LPS + vehicle.
This and the above-noted HAL + AM findings prompt further
research into the putative “antipsychotic-like” effects of AM.
No other treatment had any noteworthy effects on locomotor
activity (Figure 3), although the locomotor effects described for
AM may complicate interpretation of swimming behavior in the
FST (see below).
The negative symptoms of schizophrenia comprise affective
flattening, alogia, anhedonia, asociality, and avolition (lack
of motivation) (98), congruent with the basic symptoms of
depression (99). Although the FST assesses behavioral despair,
it has been suggested to signify an absence of motivational
behavior which is commonly seen in schizophrenia (100). Indeed,
LPS-exposed offspring presented with significant depressive-
like behaviors (increased immobility) (Figure 4A) and reduced
active coping (swimming and climbing) (Figures 4B,C), in
agreement with earlier studies (101, 102). Especially, atypical
antipsychotics may present with antidepressant activity (103,
104), while clinical (105) and preclinical (106) studies have
described the pro-depressant effects of HAL (105, 106). In
the present study, however, HAL showed a small, albeit
negligible, effect to reverse MIA-associated immobility in
the FST and reduced swimming (Figures 4A,C), although
significantly increased struggling/climbing behavior (Figure 4B).
Importantly, GML significantly decreased immobility and
increased swimming behaviors (Figures 4A,C), antidepressant
effects congruent with an earlier study in Flinders Sensitive Line
(FSL) rats (55). Interestingly, the latter study described GML’s
prominent serotonergic actions and therapeutic equivalence with
imipramine, which is shown here, too, but less emphatically
(elevated swimming) (Figure 4C). Moreover, GML is a superior
antidepressant to HAL (Figures 4A,C). Similarly, AM also
exhibited significant antidepressant-like properties regarding
its effects on immobility and swimming behavior, although
not as marked as GML alone (immobility) (Figure 4A). Of
note, GML and AM augmented the actions of HAL on
immobility (Figure 4A) with GML bolstering the HAL effect
on struggling (Figure 4B), suggesting a bolstering of HAL’s
action via mechanisms other than D2 receptor blockade. Despite
AM suppressing locomotor activity, as noted above, this action
did not affect its ability to reduce immobility and to increase
swimming in the FST, thus highlighting a psychogenic action
to bolster escape-driven behavior that is not related to, or
mediated by, an increase in locomotor activity. Given the
noted antioxidant actions of GML and its constituents, other
antioxidants like NAC (107) are also antidepressant in the FST.
Interestingly, NAC seems to have specific benefit in especially
negative-symptom schizophrenia (40, 41), thus highlighting
that antioxidants may have preferential psychopharmacological
actions as antidepressants, which is borne out in this study
as well.
Oxidative damage is implicated in the pathophysiology
and neuroprogression of schizophrenia (35–37). Schizophrenia
patients present with increased plasma lipid peroxidation (108–
110), possibly correlated with certain clinical features (111).
Adjunctive treatment with antioxidants improve symptoms in
animal models (43, 112) as well as patients with schizophrenia
(40). Prenatal LPS exposure significantly increased cortical and
striatal lipid peroxidation in offspring (Figure 5), in agreement
with previous findings (45, 113). Mouse models of oxidative
stress are associated with cognitive and motivational deficits, as
well as dysfunction of the prefrontal cortex (114). Schizophrenia
is a hyperdopaminergic state (35) where dopamine metabolism
contributes to oxidative stress by lowering glutathione (GSH)
levels, which in turn is abrogated by D1/D2 receptor antagonists
(36, 115). Importantly, HAL treatment significantly reduced lipid
peroxidation in the frontal cortex (Figure 5A), while not having
any marked effect in the striatum (Figure 5B). However, total
striatum was analyzed here, whereas it is predominantly the
ventral striatum encompassing the ventral tegmentum that is
more relevant in rodents for an association with schizophrenia
(116). The fact that HAL did not significantly reduce striatal lipid
peroxidation may also be explained by HAL’s known pro-oxidant
actions in the striatum following chronic treatment (117) and
which is associated with its long-term locomotor side effects. This
action may otherwise obscure any possible antioxidant abilities
in reducing MDA levels as was evident in the frontal cortex. This
differential pro-oxidant action for HAL in these two brain regions
is not new. In fact, Martins et al. (118) found that chronic HAL
treatment increases oxidative stress in the striatum but decreases
such levels in the cerebral cortex. Importantly, HAL still reversed
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LPS-induced PPI deficits (Figure 2), reiterating the importance
of the frontal cortex in antipsychotic action (119). Moreover,
here, we also show a frontal cortical role for its redox modulatory
actions and how this may affect behavior. The frontal cortex
is involved in cognitive processes such as working memory,
behavioral flexibility, and attention (120). With regard to the
antidepressant-like effects of GML and AM, the frontal cortex is
also implicated in the development of depression and, hence, in
antidepressant response (121, 122).
Although GML possesses antioxidant activity in vitro (123–
126), GML had no effect on striatal lipid peroxidation, although
it prompted a large effect size reduction in the frontal cortex
(Figure 5A), thus qualitatively similar to that observed with
HAL. Earlier, we found that chronic GML reversed elevated
hippocampal lipid peroxidation in FSL rats (55), although
the discrepancy between these two studies may be due to
the different translational models used and the brain region
assayed. AM also presents with antioxidant activity (58), here,
significantly and again selectively reducing LPS-induced lipid
peroxidation in the frontal cortex (Figure 5A). The absence of
obvious antioxidant actions for GML and AM in the striatum is
noteworthy, but may be related to assaying the whole striatum,
as noted for HAL earlier. The diverse antioxidant actions of
AM, viz. modulating GSH levels (127), free radical scavenging
(128), inhibiting low-density lipoprotein oxidation (129), may
afford it a more prominent antioxidant action than raw GML
in vivo. As AM is the dominant bioactive xanthone in GML
pericarp (55), it probably provides the dominant antioxidant
activity observed with the raw extract. However, the more
pronounced antioxidant action of AM does not translate into
an improved behavioral outcome for AM over GML (Figures 2,
3), while GML and AM only offered small (GML) to negligible
(AM) benefits in combination with HAL with regard to redox
markers (Figure 5A). This suggests that GML may be offering
beneficial effects through mechanisms other than antioxidant
activity alone.
Immune-inflammatory dysfunction has been extensively
reported in schizophrenia (35), specifically elevated levels of
pro-inflammatory cytokines (130), while being a protagonist
for oxidative stress (131). Pro-inflammatory cytokines have a
developmental role in the brain (132, 133) and are implicated
in the pathogenesis of neurodevelopmental disorders such
as schizophrenia (134, 135). IL-6 and TNF-α levels are
elevated in schizophrenia (136) and animal models (45, 137).
Likewise, IL-6 and TNF-α were elevated in MIA offspring
(Figures 6A,B) together with increased cortico-striatal lipid
peroxidation (Figure 5). HAL-associated reversal of elevated
IL-6 levels (Figure 6A) is consistent with clinical findings
(138, 139), although it did not alter elevated plasma TNF-
α levels (Figure 6B). Here, both GML and AM treatment
reduced elevated plasma IL-6 levels (Figure 6A), with GML,
but not AM, also reducing TNF-α levels (Figure 6B). This
suggests a broader immunosuppressant action for GML vs.
HAL or AM. AM has been shown to decrease inflammatory
cytokines following LPS induction (140), to inhibit IL-2 release
(141) and to suppress IL-6 expression (142). HAL + GML,
but not HAL + AM, successfully reversed elevated IL-6
and TNF-α levels, although not more so than HAL alone
(Figures 6A,B). In fact, HAL has immunosuppressive effects
(143) as does GML have anti-inflammatory properties (125,
144). However, that neither GML nor AM bolstered the
antioxidant effects of HAL again asserts that any beneficial effects
offered by adjunctive GML treatment may involve mechanisms
over and above inflammatory-redox processes. This warrants
further study.
These findings have significance as a catalyst for future pre-
clinical and clinical studies. Considering the important role
of inflammation in the progression of mood and psychotic
disorders, there is a growing interest in nutraceuticals with anti-
inflammatory/antioxidant activity in psychiatry. That GML and
AM have evinced therapeutic efficacy in the MIA model, as
well as possess anti-inflammatory and antioxidant properties,
suggests potential as a novel adjunctive treatment for these
disorders (145). However, there appears to be distinct differential
effects with respect to the mood–psychosis continuum, with
a bias in favor of a depressed mood component. This
prompts further investigation into GML’s clinical benefits as an
antidepressant vs. an antipsychotic. These aspects need deeper
consideration in further animal studies but also in controlled
clinical trials (146).
Certain limitations to this study are worth noting. Given the
less-than-adequate antipsychotic-like effects for GML and AM, it
would have been informative to include another schizophrenia-
like behavioral assessment in the protocol to confirm these
findings, e.g., memory, social interaction. Moreover, a dose
titration analysis for GML and AM may have revealed a dose-
dependent association in their behavioral effects, especially since
the dose used for GML was based on a prior antidepressant study
in another animal model (55).We also did not explore synergistic
effects with atypical agents, which could differ to HAL. Biological
analysis could have benefitted from regional striatal analysis, i.e.,
ventral, rostral, as opposed to assay of the whole striatum, as was
done here. The study design did not allow for the assessment of
drug treatments in healthy controls, which may have allowed for
more in-depth explanation of treatment effects in LPS-exposed
animals. Finally, having the same number of animals in both
the saline-treated and LPS-exposed groups could have been an
added benefit.
CONCLUSION
Schizophrenia is plagued by poor treatment outcomes and the
limited efficacy of currently available antipsychotics (147–149).
Supplementary treatment with nutraceutical anti-inflammatory
agents and antioxidants such as GML may offer distinct
therapeutic benefits (46). Plant extracts invariably contain a rich
mixture of various bioactive constituents, yet little is known
whether the pharmacological properties of a given extract are
the sum of one or a group of inherent constituents or the
result of the unique mix that the raw extract offers. This study
has attempted to highlight this important question. Unlike the
reference antipsychotic, HAL, chronic treatment with GML or
AM failed to impact on sensorimotor gating deficits in the
MIA model. However, both GML and AM not only displayed
significant antidepressant-like properties but also bolstered the
anti-immobility response to HAL. This is noteworthy as unlike
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atypical antipsychotics, HAL is not a recognized antidepressant,
while here, it only marginally reduced immobility in the FST.
GML and AM were both anti-inflammatory in the model,
which may underlie their antidepressant effects. AM and, to a
lesser degree, GML abrogated frontal cortical oxidative stress.
This study confirms the antidepressant-like effects of GML
described in another translational model of depression, the FSL
rat (55). Having performed this study in a MIA model supports
the use of GML and AM to address depressive symptoms
in schizophrenia. However, their ability to address broader
psychotic manifestations of the illness, e.g., PPI deficits, requires
further study. Whether GML or AM is able to confer therapeutic
benefits remains to be confirmed in dose–response and other
clinical studies (150).
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